Table 3

Proportion of patient with HBeAg loss and HBeAg seroconversion at week 48 in the HBeAg-positive patients

No. of patients (%)Besifovir 90 mg (n=18)Besifovir 150 mg (n=20)Entecavir 0.5 mg (n=21)
HBeAg loss
 N (%)3 (16.67)4 (20)3 (14.29)
 p value1.0000*0.6965*
HBeAg seroconversion
 N (%)2 (11.11)3 (15)2 (9.52)
 p Value1.0000*0.6628*
HBeAg loss with HBV DNA less than 60 IU/mL (300 copies/mL)
 N (%)3 (16.67)4 (20)3 (14.29)
 p Value1.0000*0.6965*
HBeAg loss with HBV DNA less than 20 IU/mL (116 copies/mL)
 N (%)3 (16.67)4 (20)3 (14.29)
  p Value1.0000*0.6965*
  • All the results were the same for both per-protocol and intention-to-treat analyses.

  • *p Value obtained from Fisher's exact test.

  • HBV, hepatitis B virus.